Compare Nuwellis Inc (NUWE) vs Health Care Select Sector SPDR Fund (XLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs Health Care Select Sector SPDR Fund — how do they compare? Nuwellis Inc trades at $0.69 (market cap $2.20M), while Health Care Select Sector SPDR Fund trades at $168.2 (market cap $43.48B). The key difference: Health Care Select Sector SPDR Fund is far larger — about 19763.6× Nuwellis Inc's market cap, and Health Care Select Sector SPDR Fund is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nuwellis Inc for 26 Days and Health Care Select Sector SPDR Fund for 100 Days on average.
| NUWE | XLV | |
|---|---|---|
Market Cap | $2.20M | $43.48B |
Volume | 121,544 | 11,121,431 |
Sector | Health | — |
52-Week High | $146.65 | $175.68 |
52-Week Low | $0.68 | $141.95 |
Typical Hold Time | 26 Days | 100 Days |
Enterprise Value | -$1.52M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
XLV trades at $168.81, up 1.03% today, with a bullish technical signal driven by moving averages. The ETF holds 61 healthcare stocks from the S&P 500, offering broad sector exposure at a low 0.08% expense ratio. Recent news highlights its defensive appeal amid market volatility and potential Fed rate hikes, with articles comparing it favorably to peers like IBB and PJP on cost and diversification.
Outlook is positive given healthcare's defensive growth profile and XLV's cost efficiency, but risks include political uncertainty from midterm elections and sector-specific volatility from drug trial outcomes. Wall Street sentiment is constructive, with the ETF near key resistance at $170.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About Health Care Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →
